T1	p 104 115	hypertrophy
T2	p 166 167	.
T3	p 238 243	ARB )
T4	p 283 294	ventricular
T5	p 330 382	continuous ambulatory peritoneal dialysis ( CAPD ) .
T6	p 409 425	24 CAPD patients
T7	p 454 475	mass index ( LVMi ) >
T8	p 480 524	g/m2 for women and LVMi > 137 g/m2 for men ]
T9	p 585 600	ARB valsartan (
T10	p 785 786	:
T11	p 1276 1285	diastolic
T12	p 1319 1341	treated with ARB . The
T13	p 1385 1403	treated with ARB (
T14	p 1530 1549	LVMi was associated
T15	p 1586 1599	CAPD patients
T16	p 1611 1630	ARB reduced LVMi in
T17	i 8 61	selective angiotensin receptor antagonist , Valsartan
T18	i 194 243	selective angiotensin II receptor blocker ( ARB )
T19	i 341 362	ambulatory peritoneal
T20	i 467 473	LVMi )
T21	i 499 505	LVMi >
T22	i 581 600	the ARB valsartan (
T23	i 610 622	or a placebo
T24	i 653 661	pressure
T25	i 811 821	compliance
T26	i 840 853	reflections [
T27	i 1008 1020	BP ( mercury
T28	i 1332 1337	ARB .
T29	i 1342 1346	LVMi
T30	i 1398 1403	ARB (
T31	i 1461 1470	placebo (
T32	i 1530 1534	LVMi
T33	i 1611 1627	ARB reduced LVMi
T34	o 73 86	regression of
T35	o 147 155	arterial
T36	o 442 466	ventricular mass index (
T37	o 647 668	blood pressure ( BP )
T38	o 798 909	large-artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI
T39	o 994 1010	body weight , BP
T40	o 1042 1171	serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .
T41	o 1263 1288	Systolic and diastolic BP
T42	o 1342 1346	LVMi
T43	o 1530 1534	LVMi
T44	o 1567 1582	in PWV and AI .
T45	o 1663 1686	arterial hemodynamics .